 | • レポートコード：QYR9ST04945 • 出版社/出版日：QYResearch / 2019年9月2日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、95ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療・製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| ※当調査レポートでは、代謝障害治療薬の世界市場について調査・分析し、代謝障害治療薬の世界市場規模、市場動向、主要企業別マーケットシェア、主要地域別市場規模、企業プロフィールなどの情報をまとめました。また、セグメント分析では、種類別（異染性白質ジストロフィー、グロボイド白質ジストロフィー、肝性脳症、その他）、用途別（糖尿病、肥満、高コレステロール血症、リソソーム蓄積症、その他）、地域別（北米、ヨーロッパ、中国、日本国内、東南アジア、インド、中南米）に区分して市場規模を算出しました。 ・レポートの概要 ・世界の代謝障害治療薬市場動向 ・主要企業別マーケットシェア ・代謝障害治療薬の種類別市場規模2014-2019 （異染性白質ジストロフィー、グロボイド白質ジストロフィー、肝性脳症、その他） ・代謝障害治療薬の用途別市場規模2014-2019 （糖尿病、肥満、高コレステロール血症、リソソーム蓄積症、その他） ・代謝障害治療薬の北米市場：主要企業・種類別/用途別市場規模 ・代謝障害治療薬のヨーロッパ市場：主要企業・種類別/用途別市場規模 ・代謝障害治療薬の中国市場：主要企業・種類別/用途別市場規模 ・代謝障害治療薬の日本国内市場：主要企業・種類別/用途別市場規模 ・代謝障害治療薬の東南アジア市場：主要企業・種類別/用途別市場規模 ・代謝障害治療薬のインド市場：主要企業・種類別/用途別市場規模 ・代謝障害治療薬の中南米市場：主要企業・種類別/用途別市場規模 ・主要企業のプロフィール （AbbVie、Novo Nordisk、Actelion Pharmaceuticals、Sanofi、Biocon、Merck、Boehringer Ingelheim、AstraZeneca、CymaBay Therapeutics、Eli Lilly and Company） ・代謝障害治療薬の市場規模予測2019-2025 （種類別、用途別、地域別市場予測） ・アナリストの観点・結論 ... |
Metabolic Disorders Therapeutics is a drug used to treat the symptoms of metabolic disorders caused by a variety of causes.Due to the increasing pressure of modern life and the spread of unhealthy lifestyles, the global metabolic disorder treatment market will continue to grow strongly during the forecast period.
In 2018, the global Metabolic Disorders Therapeutics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Metabolic Disorders Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Metabolic Disorders Therapeutics development in United States, Europe and China.
The key players covered in this study
AbbVie
Novo Nordisk
Actelion Pharmaceuticals
Sanofi
Biocon
Merck
Boehringer Ingelheim
AstraZeneca
CymaBay Therapeutics
Eli Lilly and Company
Market segment by Type, the product can be split into
Metachromatic Leukodystrophy
Globoid Leukodystrophy
Hepatic Encephalopathy
Others
Market segment by Application, split into
Diabetes
Obesity
Hypercholesterolemia
Lysosomal Storage Diseases
Others
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Metabolic Disorders Therapeutics status, future forecast, growth opportunity, key market and key players.
To present the Metabolic Disorders Therapeutics development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Metabolic Disorders Therapeutics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Metabolic Disorders Therapeutics Market Size Growth Rate by Type (2014-2025)
1.4.2 Metachromatic Leukodystrophy
1.4.3 Globoid Leukodystrophy
1.4.4 Hepatic Encephalopathy
1.4.5 Others
1.5 Market by Application
1.5.1 Global Metabolic Disorders Therapeutics Market Share by Application (2014-2025)
1.5.2 Diabetes
1.5.3 Obesity
1.5.4 Hypercholesterolemia
1.5.5 Lysosomal Storage Diseases
1.5.6 Others
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Metabolic Disorders Therapeutics Market Size
2.2 Metabolic Disorders Therapeutics Growth Trends by Regions
2.2.1 Metabolic Disorders Therapeutics Market Size by Regions (2014-2025)
2.2.2 Metabolic Disorders Therapeutics Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities
3 Market Share by Key Players
3.1 Metabolic Disorders Therapeutics Market Size by Manufacturers
3.1.1 Global Metabolic Disorders Therapeutics Revenue by Manufacturers (2014-2019)
3.1.2 Global Metabolic Disorders Therapeutics Revenue Market Share by Manufacturers (2014-2019)
3.1.3 Global Metabolic Disorders Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2 Metabolic Disorders Therapeutics Key Players Head office and Area Served
3.3 Key Players Metabolic Disorders Therapeutics Product/Solution/Service
3.4 Date of Enter into Metabolic Disorders Therapeutics Market
3.5 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type and Application
4.1 Global Metabolic Disorders Therapeutics Market Size by Type (2014-2019)
4.2 Global Metabolic Disorders Therapeutics Market Size by Application (2014-2019)
5 United States
5.1 United States Metabolic Disorders Therapeutics Market Size (2014-2019)
5.2 Metabolic Disorders Therapeutics Key Players in United States
5.3 United States Metabolic Disorders Therapeutics Market Size by Type
5.4 United States Metabolic Disorders Therapeutics Market Size by Application
6 Europe
6.1 Europe Metabolic Disorders Therapeutics Market Size (2014-2019)
6.2 Metabolic Disorders Therapeutics Key Players in Europe
6.3 Europe Metabolic Disorders Therapeutics Market Size by Type
6.4 Europe Metabolic Disorders Therapeutics Market Size by Application
7 China
7.1 China Metabolic Disorders Therapeutics Market Size (2014-2019)
7.2 Metabolic Disorders Therapeutics Key Players in China
7.3 China Metabolic Disorders Therapeutics Market Size by Type
7.4 China Metabolic Disorders Therapeutics Market Size by Application
8 Japan
8.1 Japan Metabolic Disorders Therapeutics Market Size (2014-2019)
8.2 Metabolic Disorders Therapeutics Key Players in Japan
8.3 Japan Metabolic Disorders Therapeutics Market Size by Type
8.4 Japan Metabolic Disorders Therapeutics Market Size by Application
9 Southeast Asia
9.1 Southeast Asia Metabolic Disorders Therapeutics Market Size (2014-2019)
9.2 Metabolic Disorders Therapeutics Key Players in Southeast Asia
9.3 Southeast Asia Metabolic Disorders Therapeutics Market Size by Type
9.4 Southeast Asia Metabolic Disorders Therapeutics Market Size by Application
10 India
10.1 India Metabolic Disorders Therapeutics Market Size (2014-2019)
10.2 Metabolic Disorders Therapeutics Key Players in India
10.3 India Metabolic Disorders Therapeutics Market Size by Type
10.4 India Metabolic Disorders Therapeutics Market Size by Application
11 Central & South America
11.1 Central & South America Metabolic Disorders Therapeutics Market Size (2014-2019)
11.2 Metabolic Disorders Therapeutics Key Players in Central & South America
11.3 Central & South America Metabolic Disorders Therapeutics Market Size by Type
11.4 Central & South America Metabolic Disorders Therapeutics Market Size by Application
12 International Players Profiles
12.1 AbbVie
12.1.1 AbbVie Company Details
12.1.2 Company Description and Business Overview
12.1.3 Metabolic Disorders Therapeutics Introduction
12.1.4 AbbVie Revenue in Metabolic Disorders Therapeutics Business (2014-2019)
12.1.5 AbbVie Recent Development
12.2 Novo Nordisk
12.2.1 Novo Nordisk Company Details
12.2.2 Company Description and Business Overview
12.2.3 Metabolic Disorders Therapeutics Introduction
12.2.4 Novo Nordisk Revenue in Metabolic Disorders Therapeutics Business (2014-2019)
12.2.5 Novo Nordisk Recent Development
12.3 Actelion Pharmaceuticals
12.3.1 Actelion Pharmaceuticals Company Details
12.3.2 Company Description and Business Overview
12.3.3 Metabolic Disorders Therapeutics Introduction
12.3.4 Actelion Pharmaceuticals Revenue in Metabolic Disorders Therapeutics Business (2014-2019)
12.3.5 Actelion Pharmaceuticals Recent Development
12.4 Sanofi
12.4.1 Sanofi Company Details
12.4.2 Company Description and Business Overview
12.4.3 Metabolic Disorders Therapeutics Introduction
12.4.4 Sanofi Revenue in Metabolic Disorders Therapeutics Business (2014-2019)
12.4.5 Sanofi Recent Development
12.5 Biocon
12.5.1 Biocon Company Details
12.5.2 Company Description and Business Overview
12.5.3 Metabolic Disorders Therapeutics Introduction
12.5.4 Biocon Revenue in Metabolic Disorders Therapeutics Business (2014-2019)
12.5.5 Biocon Recent Development
12.6 Merck
12.6.1 Merck Company Details
12.6.2 Company Description and Business Overview
12.6.3 Metabolic Disorders Therapeutics Introduction
12.6.4 Merck Revenue in Metabolic Disorders Therapeutics Business (2014-2019)
12.6.5 Merck Recent Development
12.7 Boehringer Ingelheim
12.7.1 Boehringer Ingelheim Company Details
12.7.2 Company Description and Business Overview
12.7.3 Metabolic Disorders Therapeutics Introduction
12.7.4 Boehringer Ingelheim Revenue in Metabolic Disorders Therapeutics Business (2014-2019)
12.7.5 Boehringer Ingelheim Recent Development
12.8 AstraZeneca
12.8.1 AstraZeneca Company Details
12.8.2 Company Description and Business Overview
12.8.3 Metabolic Disorders Therapeutics Introduction
12.8.4 AstraZeneca Revenue in Metabolic Disorders Therapeutics Business (2014-2019)
12.8.5 AstraZeneca Recent Development
12.9 CymaBay Therapeutics
12.9.1 CymaBay Therapeutics Company Details
12.9.2 Company Description and Business Overview
12.9.3 Metabolic Disorders Therapeutics Introduction
12.9.4 CymaBay Therapeutics Revenue in Metabolic Disorders Therapeutics Business (2014-2019)
12.9.5 CymaBay Therapeutics Recent Development
12.10 Eli Lilly and Company
12.10.1 Eli Lilly and Company Company Details
12.10.2 Company Description and Business Overview
12.10.3 Metabolic Disorders Therapeutics Introduction
12.10.4 Eli Lilly and Company Revenue in Metabolic Disorders Therapeutics Business (2014-2019)
12.10.5 Eli Lilly and Company Recent Development
13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details
Table Metabolic Disorders Therapeutics Key Market Segments
Table Key Players Metabolic Disorders Therapeutics Covered
Table Global Metabolic Disorders Therapeutics Market Size Growth Rate by Type 2014-2025 (Million US$)
Figure Global Metabolic Disorders Therapeutics Market Size Market Share by Type 2014-2025
Figure Metachromatic Leukodystrophy Figures
Table Key Players of Metachromatic Leukodystrophy
Figure Globoid Leukodystrophy Figures
Table Key Players of Globoid Leukodystrophy
Figure Hepatic Encephalopathy Figures
Table Key Players of Hepatic Encephalopathy
Figure Others Figures
Table Key Players of Others
Table Global Metabolic Disorders Therapeutics Market Size Growth by Application 2014-2025 (Million US$)
Figure Diabetes Case Studies
Figure Obesity Case Studies
Figure Hypercholesterolemia Case Studies
Figure Lysosomal Storage Diseases Case Studies
Figure Others Case Studies
Figure Metabolic Disorders Therapeutics Report Years Considered
Table Global Metabolic Disorders Therapeutics Market Size 2014-2025 (Million US$)
Figure Global Metabolic Disorders Therapeutics Market Size and Growth Rate 2014-2025 (Million US$)
Table Global Metabolic Disorders Therapeutics Market Size by Regions 2014-2025 (Million US$)
Table Global Metabolic Disorders Therapeutics Market Size by Regions 2014-2019 (Million US$)
Table Global Metabolic Disorders Therapeutics Market Share by Regions 2014-2019
Figure Global Metabolic Disorders Therapeutics Market Share by Regions 2014-2019
Figure Global Metabolic Disorders Therapeutics Market Share by Regions 2019
Table Market Top Trends
Table Global Metabolic Disorders Therapeutics Revenue by Manufacturers (2014-2019) (Million US$)
Table Global Metabolic Disorders Therapeutics Market Share by Manufacturers (2014-2019)
Figure Global Metabolic Disorders Therapeutics Market Share by Manufacturers in 2018
Table Global Metabolic Disorders Therapeutics Manufacturers Market Concentration Ratio (CR5 and HHI)
Table Key Players Head office and Area Served
Table Key Players Metabolic Disorders Therapeutics Product/Solution/Service
Table Date of Enter into Metabolic Disorders Therapeutics Market
Table Mergers & Acquisitions, Expansion Plans
Table Global Metabolic Disorders Therapeutics Market Size by Type (2014-2019) (Million US$)
Table Global Metabolic Disorders Therapeutics Market Size Share by Type (2014-2019)
Figure Global Metabolic Disorders Therapeutics Market Size Market Share by Type (2014-2019)
Table Global Metabolic Disorders Therapeutics Market Size by Application (2014-2019) (Million US$)
Table Global Metabolic Disorders Therapeutics Market Size Share by Application (2014-2019)
Figure Global Metabolic Disorders Therapeutics Market Size Market Share by Application (2014-2019)
Figure Global Metabolic Disorders Therapeutics Revenue Market Share by Application in 2018
Figure United States Metabolic Disorders Therapeutics Market Size 2014-2019 (Million US$)
Table United States Key Players Metabolic Disorders Therapeutics Revenue (2018-2019) (Million US$)
Table United States Key Players Metabolic Disorders Therapeutics Market Share (2018-2019)
Table United States Metabolic Disorders Therapeutics Market Size by Type (2014-2019) (Million US$)
Table United States Metabolic Disorders Therapeutics Market Share by Type (2014-2019)
Table United States Metabolic Disorders Therapeutics Market Size by Application (2014-2019) (Million US$)
Table United States Metabolic Disorders Therapeutics Market Share by Application (2014-2019)
Figure Europe Metabolic Disorders Therapeutics Market Size 2014-2019 (Million US$)
Table Europe Key Players Metabolic Disorders Therapeutics Revenue (2018-2019) (Million US$)
Table Europe Key Players Metabolic Disorders Therapeutics Market Share (2018-2019)
Table Europe Metabolic Disorders Therapeutics Market Size by Type (2014-2019) (Million US$)
Table Europe Metabolic Disorders Therapeutics Market Share by Type (2014-2019)
Table Europe Metabolic Disorders Therapeutics Market Size by Application (2014-2019) (Million US$)
Table Europe Metabolic Disorders Therapeutics Market Share by Application (2014-2019)
Figure China Metabolic Disorders Therapeutics Market Size 2014-2019 (Million US$)
Table China Key Players Metabolic Disorders Therapeutics Revenue (2018-2019) (Million US$)
Table China Key Players Metabolic Disorders Therapeutics Market Share (2018-2019)
Table China Metabolic Disorders Therapeutics Market Size by Type (2014-20189) (Million US$)
Table China Metabolic Disorders Therapeutics Market Share by Type (2014-2019)
Table China Metabolic Disorders Therapeutics Market Size by Application (2014-2019) (Million US$)
Table China Metabolic Disorders Therapeutics Market Share by Application (2014-2019)
Figure Japan Metabolic Disorders Therapeutics Market Size 2014-2019 (Million US$)
Table Japan Key Players Metabolic Disorders Therapeutics Revenue (2018-2019) (Million US$)
Table Japan Key Players Metabolic Disorders Therapeutics Market Share (2018-2019)
Table Japan Metabolic Disorders Therapeutics Market Size by Type (2014-2019) (Million US$)
Table Japan Metabolic Disorders Therapeutics Market Share by Type (2014-2019)
Table Japan Metabolic Disorders Therapeutics Market Size by Application (2014-2019) (Million US$)
Table Japan Metabolic Disorders Therapeutics Market Share by Application (2014-2019)
Figure Southeast Asia Metabolic Disorders Therapeutics Market Size 2014-2019 (Million US$)
Table Southeast Asia Key Players Metabolic Disorders Therapeutics Revenue (2018-2019) (Million US$)
Table Southeast Asia Key Players Metabolic Disorders Therapeutics Market Share (2018-2019)
Table Southeast Asia Metabolic Disorders Therapeutics Market Size by Type (2014-2019) (Million US$)
Table Southeast Asia Metabolic Disorders Therapeutics Market Share by Type (2014-2019)
Table Southeast Asia Metabolic Disorders Therapeutics Market Size by Application (2014-2019) (Million US$)
Table Southeast Asia Metabolic Disorders Therapeutics Market Share by Application (2014-2019)
Figure India Metabolic Disorders Therapeutics Market Size 2014-2019 (Million US$)
Table India Key Players Metabolic Disorders Therapeutics Revenue (2018-2019) (Million US$)
Table India Key Players Metabolic Disorders Therapeutics Market Share (2018-2019)
Table India Metabolic Disorders Therapeutics Market Size by Type (2014-2019) (Million US$)
Table India Metabolic Disorders Therapeutics Market Share by Type (2014-2019)
Table India Metabolic Disorders Therapeutics Market Size by Application (2014-2019) (Million US$)
Table India Metabolic Disorders Therapeutics Market Share by Application (2014-2019)
Figure Central & South America Metabolic Disorders Therapeutics Market Size 2014-2019 (Million US$)
Table Central & South America Key Players Metabolic Disorders Therapeutics Revenue (2018-2019) (Million US$)
Table Central & South America Key Players Metabolic Disorders Therapeutics Market Share (2018-2019)
Table Central & South America Metabolic Disorders Therapeutics Market Size by Type (2014-2019) (Million US$)
Table Central & South America Metabolic Disorders Therapeutics Market Share by Type (2014-2019)
Table Central & South America Metabolic Disorders Therapeutics Market Size by Application (2014-2019) (Million US$)
Table Central & South America Metabolic Disorders Therapeutics Market Share by Application (2014-2019)
Table AbbVie Company Details
Table AbbVie Revenue in Metabolic Disorders Therapeutics Business (2014-2019) (Million US$)
Figure AbbVie Revenue Growth Rate in Metabolic Disorders Therapeutics Business (2014-2019)
Table AbbVie Recent Development
Table Novo Nordisk Company Details
Table Novo Nordisk Revenue in Metabolic Disorders Therapeutics Business (2014-2019)(Million US$)
Figure Novo Nordisk Revenue Growth Rate in Metabolic Disorders Therapeutics Business (2014-2019)
Table Novo Nordisk Recent Development
Table Actelion Pharmaceuticals Company Details
Table Actelion Pharmaceuticals Revenue in Metabolic Disorders Therapeutics Business (2014-2019)(Million US$)
Figure Actelion Pharmaceuticals Revenue Growth Rate in Metabolic Disorders Therapeutics Business (2014-2019)
Table Actelion Pharmaceuticals Recent Development
Table Sanofi Company Details
Table Sanofi Revenue in Metabolic Disorders Therapeutics Business (2014-2019)(Million US$)
Figure Sanofi Revenue Growth Rate in Metabolic Disorders Therapeutics Business (2014-2019)
Table Sanofi Recent Development
Table Biocon Company Details
Table Biocon Revenue in Metabolic Disorders Therapeutics Business (2014-2019)(Million US$)
Figure Biocon Revenue Growth Rate in Metabolic Disorders Therapeutics Business (2014-2019)
Table Biocon Recent Development
Table Merck Company Details
Table Merck Revenue in Metabolic Disorders Therapeutics Business (2014-2019)(Million US$)
Figure Merck Revenue Growth Rate in Metabolic Disorders Therapeutics Business (2014-2019)
Table Merck Recent Development
Table Boehringer Ingelheim Company Details
Table Boehringer Ingelheim Revenue in Metabolic Disorders Therapeutics Business (2014-2019)(Million US$)
Figure Boehringer Ingelheim Revenue Growth Rate in Metabolic Disorders Therapeutics Business (2014-2019)
Table Boehringer Ingelheim Recent Development
Table AstraZeneca Company Details
Table AstraZeneca Revenue in Metabolic Disorders Therapeutics Business (2014-2019)(Million US$)
Figure AstraZeneca Revenue Growth Rate in Metabolic Disorders Therapeutics Business (2014-2019)
Table AstraZeneca Recent Development
Table CymaBay Therapeutics Company Details
Table CymaBay Therapeutics Revenue in Metabolic Disorders Therapeutics Business (2014-2019)(Million US$)
Figure CymaBay Therapeutics Revenue Growth Rate in Metabolic Disorders Therapeutics Business (2014-2019)
Table CymaBay Therapeutics Recent Development
Table Eli Lilly and Company Company Details
Table Eli Lilly and Company Revenue in Metabolic Disorders Therapeutics Business (2014-2019)(Million US$)
Figure Eli Lilly and Company Revenue Growth Rate in Metabolic Disorders Therapeutics Business (2014-2019)
Table Eli Lilly and Company Recent Development
Table Global Metabolic Disorders Therapeutics Market Size by Regions (Million US$) 2019-2025
Figure Global Metabolic Disorders Therapeutics Market Size Share by Regions (2019-2025)
Figure Global Metabolic Disorders Therapeutics Market Size Share by Regions in 2025
Figure United States Metabolic Disorders Therapeutics Market Size Forecast (2019-2025)(Million USD)
Figure Europe Metabolic Disorders Therapeutics Market Size Forecast (2019-2025)(Million USD)
Figure China Metabolic Disorders Therapeutics Market Size Forecast (2019-2025)(Million USD)
Figure Japan Metabolic Disorders Therapeutics Market Size Forecast (2019-2025)(Million USD)
Figure Southeast Asia Metabolic Disorders Therapeutics Market Size Forecast (2019-2025)(Million USD)
Figure India Metabolic Disorders Therapeutics Market Size Forecast (2019-2025)(Million USD)
Figure Central & South America Metabolic Disorders Therapeutics Market Size Forecast (2019-2025)(Million USD)
Table Global Metabolic Disorders Therapeutics Market Size by Product (2019-2025) (Million US$)
Figure Global Metabolic Disorders Therapeutics Market Size by Product (2019-2025)
Figure Global Metabolic Disorders Therapeutics Market Size by Product in 2025
Table Global Metabolic Disorders Therapeutics Market Size by Application (2019-2025) (Million US$)
Figure Global Metabolic Disorders Therapeutics Market Size by Application (2019-2025)
Figure Global Metabolic Disorders Therapeutics Market Size by Application in 2025
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources
中枢神経系疾患治療法の世界市場：市場規模・現状・予測 Central Nervous System (CNS) disorders are also called as neurological and psychiatric disorders. CNS disorders can affect either the brain or spinal cord, or both. Depression is the dominated market of CNS Disorders Therapeutics In 2018, the global Central Nervous System Disorders Therapeutics mark…- メタボリックシンドロームの世界市場：市場規模・現状・予測 Metabolic syndrome is a cluster of conditions — increased blood pressure, high blood sugar, excess body fat around the waist, and abnormal cholesterol or triglyceride levels — that occur together, increasing your risk of heart disease, stroke and diabetes.One of the upcoming trends gaining traction …
- 筋骨格障害治療薬の世界市場：市場規模・現状・予測 Musculoskeletal disorders are the group of pain disorders or injuries that affect the body's joints, muscles, nerves, ligaments, tendons, and structures, all of which support the hands, legs, neck and back. The pain and discomfort vary with the severity of the condition. These disorders have a wide …
- 高コレステロール血症治療の世界市場：市場規模・現状・予測 Hypercholesterolemia is a genetic disorder characterized by very high levels of cholesterol in the blood. Hypercholesterolemia, also termed as dyslipidemia, is a form of hyperlipidemia and hyperlipoproteinemia in the body. Presence of low-density Lipoprotein Cholesterol (LDL-C) or bad cholesterol in…
- 世界の肝性脳症薬市場：専門的調査 Hepatic encephalopathy (HE) is a severe complication of TIPS treatment in patients with cirrhosis and variceal bleeding. Lactulose, is considered the first-line therapeutic agent for treating hepatic encephalopathy. Based on route of administration, Hepatic Encephalopathy Drugs include oral (tablets…